Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells

Experimental and Molecular Pathology

Volumn 96, Issue 3, 2014, Pages 367-374

  Santos, Mark F ^a   Mannam, Venkat K R ^a   Craft, Barbara S ^a   Puneky, Louis V ^a   Sheehan, Natale T ^a   Lewis, Robert E ^a   Cruse, Julius M ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Circulating tumor cells; Innate immunity; Metastatic cancer; Natural killer cells; Toll like receptors

Indexed keywords

TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ANALYTICAL EQUIPMENT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CELL COUNT; CIRCULATING TUMOR CELL; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INNATE IMMUNITY; K562 CELL LINE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PROSTATE CANCER; PROTEIN EXPRESSION;

CIRCULATING TUMOR CELLS; INNATE IMMUNITY; METASTATIC CANCER; NATURAL KILLER CELLS; TOLL-LIKE RECEPTORS;

BREAST NEOPLASMS; CELL COUNT; COLORECTAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, INNATE; K562 CELLS; KILLER CELLS, NATURAL; MALE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSTATIC NEOPLASMS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84899498472     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.04.001     Document Type: Article

References (36)

1. Bellora F., Castriconi R., Dondero A., Carrega P., Mantovani A., Ferlazzo G., Moretta A., Bottino C. Human NK cells and NK receptors. Immunol. Lett. 2013, (Electronic publication ahead of print). 10.1016/j.imlet.2013.12.009.
2. Bottley G., Cook G.P., Blair G.E. A flow cytometric assay for analysis of natural-killer cell-mediated cytolysis of adenovirus-transformed cells. Adenovirus methods and protocols 2007, 221-230. Humana Press, Totowa, NJ. W.S.M. Wold, A.E. Tollefson (Eds.).
3. Bryceson Y.T., Fauriat C., Nunes J.M., Wood S.M., Björkström N.K., Long E.O., Ljunggren H.-G. Functional analysis of human NK cells by flow cytometry. Methods Mol. Biol. 2010, 612:335-352.
4. Cohen S.J., Punt C.J.A., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M., Mitchell E., Miller M.C., Doyle G.V., Tissing H., Terstappen L.W.M.M., Meropol N.J. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. JCO 2008, 26:3213-3221.
5. Cristofanilli M., Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., Doyle G.V., Matera J., Allard W.J., Miller M.C., Fritsche H.A., Hortobagyi G.N., Terstappen L.W.M.M. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 2005, 23:1420-1430.
6. De Bono J.S., Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., Doyle G.V., Terstappen L.W.W.M., Pienta K.J., Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008, 14:6302-6309.
7. Ehrentraut H., Meyer R., Schwederski M., Ehrentraut S., Velten M., Grohé C., Knuefermann P., Baumgarten G., Boehm O. Systemically administered ligands of Toll-like receptor 2, -4, and -9 induce distinct inflammatory responses in the murine lung. Mediators Inflamm. 2011, 2011:746532.
8. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants?. J. Leukoc. Biol. 2010, 87:989-999.
9. Flo T.H., Halaas Ø., Torp S., Ryan L., Lien E., Dybdahl B., Sundan A., Espevik T. Differential expression of Toll-like receptor 2 in human cells. J. Leukoc. Biol. 2001, 69:474-481.
10. Fregni G., Messaoudene M., Fourmentraux-Neves E., Mazouz-Dorval S., Chanal J., Maubec E., Marinho E., Scheer-Senyarich I., Cremer I., Avril M.-F., Caignard A. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One 2013, 8:e76928.
11. Green T.L., Craft B.S., Cruse J.M., Lewis R.E. Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. Exp. Mol. Pathol. 2013, 95:174-179.
12. Halama N., Braun M., Kahlert C., Spille A., Quack C., Rahbari N., Koch M., Weitz J., Kloor M., Zoernig I., Schirmacher P., Brand K., Grabe N., Falk C.S. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin. Cancer Res. 2011, 17:678-689.
13. Han X., Papadopoulos A.J., Ruparelia V., Devaja O., Raju K.S. Tumor lymphocytes in patients with advanced ovarian cancer: changes during in vitro culture and implications for immunotherapy. Gynecol. Oncol. 1997, 65:391-398.
14. Hayes D.F., Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Miller M.C., Matera J., Allard W.J., Doyle G.V., Terstappen L.W.W.M. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 2006, 12:4218-4224.
15. Hoshino T., Hara A., Inoue M., Honda J., Imai Y., Oizumi K., Yokoyama M.M. Flow cytometric measurement of NK cell cytotoxicity. J. Clin. Lab. Immunol. 1991, 36:39-43.
16. Jewett A., Tseng H. Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J. Cancer 2011, 443.
17. Jin T., Peng H., Wu H. Clinical value of circulating liver cancer cells for the diagnosis of hepatocellular carcinoma: A meta-analysis. Biomed. Rep. 2013, 1:731-736.
18. Kanevskiy L.M., Telford W.G., Sapozhnikov A.M., Kovalenko E.I. Lipopolysaccharide induces IFN-γ production in human NK cells. Front. Immunol. 2013, 4:11.
19. Kim G., Donnenberg V., Donnenberg A., Gooding W., Whiteside T. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: Comparisons to a 4h 51Cr-release assay. J. Immunol. Methods 2007, 325:51-66.
20. Kloss M., Decker P., Baltz K.M., Baessler T., Jung G., Rammensee H.-G., Steinle A., Krusch M., Salih H.R. Interaction of monocytes with NK cells upon toll-like receptor-induced expression of the NKG2D ligand MICA. J. Immunol. 2008, 181:6711-6719.
21. Lahat N., Alexander B., Levin D.R., Moskovitz B. The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate. Cancer Immunol. Immunother. 1989, 28:208-212.
22. Lianidou E.S., Strati A., Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit. Rev. Clin. Lab. Sci. 2014, (Electronic publication ahead of print). 10.3109/10408363.2014.896316.
23. Martinez J., Huang X., Yang Y. Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog. 2010, 6:e1000811.
24. Miescher S., Stoeck M., Qiao L., Barras C., Barrelet L., von Fliedner V. Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. Cancer Res. 1988, 48:6992-6998.
25. Nastaly P., Ruf C.G., Becker P., Bednarz-Knoll N., Stoupiec M., Kavsur R., Isbarn H., Matthies C., Wagner W., Höppner D., Fisch M., Bokemeyer C., Ahyai S., Honecker F., Riethdorf S., Pantel K. Circulating tumor cells in patients with testicular germ cell tumors. Clin. Cancer Res. 2014.
26. Plaks V., Koopman C.D., Werb Z. Circulating tumor cells. Science 2013, 341:1186-1188.
27. Rayet B., Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18:6938-6947. 10.1038/sj.onc.1203221.
28. Sabroe I., Jones E.C., Usher L.R., Whyte M.K.B., Dower S.K. Toll-like receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: A critical role for monocytes in leukocyte lipopolysaccharide responses. J. Immunol. 2002, 168:4701-4710.
29. Souza-Fonseca-Guimaraes F., Parlato M., Philippart F., Misset B., Cavaillon J.-M., Adib-Conquy M., the Captain study group Toll-like receptors expression and interferon-γ production by NK cells in human sepsis. Crit. Care 2012, 16:R206.
30. Tadema H., Abdulahad W.H., Stegeman C.A., Kallenberg C.G.M., Heeringa P. Increased expression of toll-like receptors by monocytes and natural killer cells in ANCA-associated vasculitis. PLoS One 2011, 6:e24315.
31. Teruel A., Romero M., Cacalano N.A., Head C., Jewett A. Potential contribution of naïve immune effectors to oral tumor resistance: role in synergistic induction of VEGF, IL-6, and IL-8 secretion. Cancer Immunol. Immunother. 2008, 57:359-366.
32. Tseng H.-C., Arasteh A., Paranjpe A., Teruel A., Yang W., Behel A., Alva J.A., Walter G., Head C., Ishikawa T., Herschman H.R., Cacalano N., Pyle A.D., Park N.-H., Jewett A. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One 2010, 5:e11590.
33. Tsuboi I., Tanaka H., Nakao M., Shichijo S., Itoh K. Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production. Cytokine 1995, 7:372-379.
34. Yang F.C., Agematsu K., Nakazawa T., Mori T., Ito S., Kobata T., Morimoto C., Komiyama A. CD27/CD70 interaction directly induces natural killer cell killing activity. 1Immunology 1996, 88:289-293.
35. Yu L., Wang L., Chen S. Endogenous toll-like receptor ligands and their biological significance. J. Cell. Mol. Med. 2010, 14:2592-2603.
36. Zamai L., Ponti C., Mirandola P., Gobbi G., Papa S., Galeotti L., Cocco L., Vitale M. NK cells and cancer. J. Immunol. 2007, 178:4011-4016.